 Theresa Grover
Concepts (286)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hernias, Diaphragmatic, Congenital | 13 | 2022 | 184 | 3.600 |
Why?
| | Intensive Care Units, Neonatal | 24 | 2023 | 176 | 2.360 |
Why?
| | Extracorporeal Membrane Oxygenation | 6 | 2021 | 241 | 1.790 |
Why?
| | Catheterization, Central Venous | 5 | 2021 | 83 | 1.310 |
Why?
| | Infant, Newborn | 41 | 2023 | 5038 | 1.260 |
Why?
| | Infant, Premature | 7 | 2019 | 478 | 1.190 |
Why?
| | Central Venous Catheters | 4 | 2021 | 40 | 0.900 |
Why?
| | Catheter-Related Infections | 4 | 2017 | 61 | 0.850 |
Why?
| | Pulmonary Circulation | 12 | 2011 | 407 | 0.740 |
Why?
| | Bronchopulmonary Dysplasia | 7 | 2019 | 333 | 0.740 |
Why?
| | Hypertension, Pulmonary | 11 | 2021 | 1736 | 0.690 |
Why?
| | Catheterization, Peripheral | 1 | 2021 | 100 | 0.670 |
Why?
| | Bottle Feeding | 1 | 2019 | 20 | 0.640 |
Why?
| | Cross Infection | 2 | 2018 | 194 | 0.640 |
Why?
| | Postoperative Complications | 4 | 2021 | 2122 | 0.630 |
Why?
| | Infant Formula | 1 | 2019 | 74 | 0.610 |
Why?
| | Lung | 8 | 2011 | 3521 | 0.580 |
Why?
| | Practice Guidelines as Topic | 5 | 2020 | 1381 | 0.570 |
Why?
| | Parenteral Nutrition, Total | 1 | 2017 | 27 | 0.560 |
Why?
| | Vascular Endothelial Growth Factor A | 5 | 2007 | 496 | 0.560 |
Why?
| | Quality Improvement | 7 | 2023 | 944 | 0.550 |
Why?
| | Weight Gain | 2 | 2017 | 453 | 0.550 |
Why?
| | Infant | 21 | 2023 | 7943 | 0.540 |
Why?
| | Bacterial Infections | 1 | 2018 | 217 | 0.520 |
Why?
| | Enteral Nutrition | 1 | 2017 | 157 | 0.500 |
Why?
| | Fetus | 12 | 2020 | 698 | 0.500 |
Why?
| | Intensive Care, Neonatal | 4 | 2020 | 39 | 0.490 |
Why?
| | High-Frequency Ventilation | 1 | 2015 | 41 | 0.490 |
Why?
| | Developmental Disabilities | 1 | 2018 | 236 | 0.480 |
Why?
| | Intersectoral Collaboration | 1 | 2015 | 55 | 0.470 |
Why?
| | Sheep | 17 | 2011 | 761 | 0.470 |
Why?
| | Patient Education as Topic | 1 | 2019 | 666 | 0.470 |
Why?
| | Gestational Age | 11 | 2018 | 761 | 0.460 |
Why?
| | Length of Stay | 4 | 2019 | 957 | 0.450 |
Why?
| | Hospitalization | 3 | 2021 | 1762 | 0.440 |
Why?
| | Infant, Premature, Diseases | 1 | 2014 | 88 | 0.420 |
Why?
| | Anti-Bacterial Agents | 3 | 2019 | 1471 | 0.420 |
Why?
| | Bacteremia | 3 | 2019 | 160 | 0.410 |
Why?
| | Surgical Procedures, Operative | 1 | 2014 | 206 | 0.390 |
Why?
| | Parents | 1 | 2019 | 1181 | 0.370 |
Why?
| | Anesthesia | 2 | 2023 | 117 | 0.360 |
Why?
| | Vasodilation | 8 | 2011 | 418 | 0.360 |
Why?
| | Nitric Oxide Synthase | 6 | 2006 | 209 | 0.360 |
Why?
| | Pulmonary Artery | 10 | 2011 | 1024 | 0.350 |
Why?
| | Persistent Fetal Circulation Syndrome | 2 | 2011 | 132 | 0.320 |
Why?
| | Survival Rate | 4 | 2018 | 1638 | 0.320 |
Why?
| | Retrospective Studies | 16 | 2022 | 12521 | 0.320 |
Why?
| | Urinary Tract Infections | 3 | 2019 | 131 | 0.310 |
Why?
| | Humans | 43 | 2023 | 114045 | 0.300 |
Why?
| | Nitric Oxide | 7 | 2011 | 817 | 0.300 |
Why?
| | Pregnancy | 20 | 2021 | 5499 | 0.300 |
Why?
| | Lung Diseases | 1 | 2014 | 690 | 0.300 |
Why?
| | Patient Care Bundles | 2 | 2019 | 17 | 0.290 |
Why?
| | Fetal Diseases | 3 | 2004 | 146 | 0.280 |
Why?
| | Fibrin | 1 | 2007 | 63 | 0.270 |
Why?
| | Databases, Factual | 5 | 2020 | 1125 | 0.260 |
Why?
| | Female | 33 | 2021 | 59324 | 0.250 |
Why?
| | Guanylate Cyclase | 4 | 2011 | 32 | 0.250 |
Why?
| | Infection Control | 2 | 2017 | 132 | 0.250 |
Why?
| | Pulmonary Alveoli | 2 | 2005 | 372 | 0.250 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 250 | 0.240 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2007 | 225 | 0.240 |
Why?
| | Hospital Mortality | 2 | 2019 | 773 | 0.240 |
Why?
| | Tracheostomy | 2 | 2017 | 97 | 0.230 |
Why?
| | Nitric Oxide Synthase Type III | 4 | 2007 | 181 | 0.210 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 280 | 0.210 |
Why?
| | Endothelial Growth Factors | 1 | 2002 | 49 | 0.210 |
Why?
| | Lymphokines | 1 | 2002 | 110 | 0.200 |
Why?
| | Ductus Arteriosus | 5 | 2008 | 67 | 0.200 |
Why?
| | Hemangioendothelioma | 1 | 2002 | 12 | 0.200 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 104 | 0.190 |
Why?
| | Patient Handoff | 1 | 2021 | 26 | 0.190 |
Why?
| | Uterus | 1 | 2002 | 191 | 0.190 |
Why?
| | Bradycardia | 1 | 2021 | 48 | 0.180 |
Why?
| | Neuromuscular Blockade | 1 | 2021 | 22 | 0.180 |
Why?
| | Hepatitis B Vaccines | 1 | 2021 | 46 | 0.180 |
Why?
| | Retrognathia | 1 | 2020 | 4 | 0.180 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2002 | 347 | 0.180 |
Why?
| | Micrognathism | 1 | 2020 | 10 | 0.180 |
Why?
| | Hepatitis B | 1 | 2021 | 51 | 0.180 |
Why?
| | Betamethasone | 1 | 2000 | 19 | 0.180 |
Why?
| | Animals, Newborn | 6 | 2009 | 777 | 0.180 |
Why?
| | Benzoates | 2 | 2011 | 38 | 0.180 |
Why?
| | Cyclic GMP | 3 | 2011 | 78 | 0.180 |
Why?
| | Analgesia | 1 | 2021 | 82 | 0.170 |
Why?
| | Incidence | 2 | 2018 | 2314 | 0.170 |
Why?
| | Logistic Models | 4 | 2020 | 1829 | 0.170 |
Why?
| | Carbon Monoxide | 1 | 2000 | 64 | 0.170 |
Why?
| | Cooperative Behavior | 3 | 2017 | 376 | 0.170 |
Why?
| | Ventricular Septum | 1 | 2019 | 9 | 0.170 |
Why?
| | Patient Discharge | 3 | 2021 | 770 | 0.170 |
Why?
| | Hypothermia | 1 | 2020 | 37 | 0.170 |
Why?
| | Intubation, Intratracheal | 1 | 2021 | 214 | 0.160 |
Why?
| | Male | 15 | 2021 | 55396 | 0.160 |
Why?
| | Neonatology | 1 | 2019 | 17 | 0.160 |
Why?
| | Food, Fortified | 1 | 2019 | 36 | 0.160 |
Why?
| | Vascular Resistance | 5 | 2011 | 340 | 0.160 |
Why?
| | Geographic Mapping | 1 | 2019 | 20 | 0.160 |
Why?
| | Perioperative Care | 1 | 2020 | 126 | 0.160 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 830 | 0.160 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2011 | 192 | 0.160 |
Why?
| | Blood Pressure | 4 | 2019 | 1531 | 0.160 |
Why?
| | Multivariate Analysis | 3 | 2018 | 1422 | 0.160 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 139 | 0.160 |
Why?
| | Hospitals, Pediatric | 2 | 2021 | 478 | 0.160 |
Why?
| | Airway Obstruction | 1 | 2020 | 160 | 0.150 |
Why?
| | Severity of Illness Index | 4 | 2018 | 2537 | 0.150 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 286 | 0.150 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2020 | 222 | 0.150 |
Why?
| | Animals | 19 | 2011 | 31565 | 0.150 |
Why?
| | Echocardiography, Doppler | 1 | 2018 | 95 | 0.150 |
Why?
| | Housing | 1 | 2019 | 114 | 0.150 |
Why?
| | Liver Neoplasms | 1 | 2002 | 504 | 0.150 |
Why?
| | Disease Models, Animal | 6 | 2011 | 3498 | 0.150 |
Why?
| | United States | 5 | 2018 | 12137 | 0.140 |
Why?
| | Odds Ratio | 2 | 2020 | 951 | 0.140 |
Why?
| | Premature Birth | 1 | 2020 | 275 | 0.140 |
Why?
| | Time Factors | 5 | 2021 | 6077 | 0.140 |
Why?
| | Patient Transfer | 1 | 2019 | 142 | 0.140 |
Why?
| | Child | 8 | 2023 | 18401 | 0.140 |
Why?
| | Heart Arrest | 1 | 2020 | 293 | 0.140 |
Why?
| | Patient Readmission | 2 | 2019 | 607 | 0.140 |
Why?
| | Continuity of Patient Care | 1 | 2019 | 252 | 0.140 |
Why?
| | Echocardiography | 1 | 2019 | 569 | 0.140 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2017 | 66 | 0.130 |
Why?
| | Respiration, Artificial | 4 | 2022 | 528 | 0.130 |
Why?
| | Infant, Small for Gestational Age | 1 | 2017 | 75 | 0.130 |
Why?
| | Infant, Extremely Premature | 1 | 2017 | 57 | 0.130 |
Why?
| | Communication | 1 | 2021 | 734 | 0.130 |
Why?
| | Antimicrobial Stewardship | 1 | 2018 | 92 | 0.130 |
Why?
| | Glucocorticoids | 1 | 2000 | 526 | 0.130 |
Why?
| | Vasoconstriction | 2 | 2008 | 177 | 0.130 |
Why?
| | Risk Adjustment | 1 | 2016 | 76 | 0.120 |
Why?
| | Clinical Nursing Research | 1 | 2015 | 10 | 0.120 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 3 | 2011 | 27 | 0.120 |
Why?
| | Heart Defects, Congenital | 1 | 2020 | 683 | 0.110 |
Why?
| | rho-Associated Kinases | 3 | 2011 | 80 | 0.110 |
Why?
| | Recombinant Proteins | 3 | 2005 | 1228 | 0.110 |
Why?
| | Pregnancy Complications, Cardiovascular | 2 | 2004 | 64 | 0.110 |
Why?
| | Program Evaluation | 1 | 2017 | 820 | 0.110 |
Why?
| | Mothers | 1 | 2019 | 650 | 0.110 |
Why?
| | Pneumonia | 1 | 2018 | 563 | 0.100 |
Why?
| | Health Services Accessibility | 1 | 2019 | 756 | 0.100 |
Why?
| | Vasodilator Agents | 2 | 2011 | 302 | 0.100 |
Why?
| | Administration, Inhalation | 2 | 2007 | 637 | 0.100 |
Why?
| | Leadership | 1 | 2015 | 291 | 0.100 |
Why?
| | Apgar Score | 2 | 2023 | 16 | 0.090 |
Why?
| | Hemodynamics | 4 | 2011 | 1015 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 1 | 2022 | 3039 | 0.090 |
Why?
| | Pyridines | 4 | 2011 | 419 | 0.090 |
Why?
| | Isoenzymes | 1 | 2011 | 283 | 0.090 |
Why?
| | Sulfones | 3 | 2005 | 97 | 0.090 |
Why?
| | Chronic Disease | 2 | 2014 | 1577 | 0.090 |
Why?
| | Infant, Low Birth Weight | 2 | 2022 | 124 | 0.080 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2011 | 236 | 0.080 |
Why?
| | Serotonin | 1 | 2011 | 292 | 0.080 |
Why?
| | Pulmonary Wedge Pressure | 2 | 2009 | 64 | 0.080 |
Why?
| | Cohort Studies | 4 | 2021 | 4883 | 0.080 |
Why?
| | Amides | 2 | 2006 | 87 | 0.070 |
Why?
| | Muscle, Smooth, Vascular | 3 | 2009 | 409 | 0.070 |
Why?
| | Immunohistochemistry | 2 | 2002 | 1624 | 0.070 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2007 | 26 | 0.070 |
Why?
| | Cardiovascular Agents | 1 | 2008 | 125 | 0.070 |
Why?
| | Immediate-Early Proteins | 1 | 2007 | 52 | 0.070 |
Why?
| | Oxadiazoles | 3 | 2011 | 32 | 0.070 |
Why?
| | Enzyme Activation | 2 | 2005 | 771 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 2 | 2008 | 784 | 0.060 |
Why?
| | Ligation | 2 | 2002 | 75 | 0.060 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2005 | 39 | 0.060 |
Why?
| | Pyrazoles | 2 | 2005 | 361 | 0.060 |
Why?
| | Birth Weight | 1 | 2007 | 439 | 0.060 |
Why?
| | Hyperoxia | 1 | 2005 | 99 | 0.060 |
Why?
| | Body Weight | 2 | 2005 | 868 | 0.060 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 388 | 0.050 |
Why?
| | Homeodomain Proteins | 1 | 2007 | 465 | 0.050 |
Why?
| | Enzyme Inhibitors | 4 | 2009 | 743 | 0.050 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2002 | 61 | 0.050 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2003 | 80 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2007 | 926 | 0.050 |
Why?
| | Prevalence | 2 | 2019 | 2247 | 0.050 |
Why?
| | Guideline Adherence | 2 | 2017 | 489 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 103 | 0.050 |
Why?
| | Airway Extubation | 1 | 2022 | 43 | 0.050 |
Why?
| | Premedication | 1 | 2021 | 36 | 0.050 |
Why?
| | Oligonucleotides | 1 | 2002 | 137 | 0.050 |
Why?
| | Pain, Postoperative | 1 | 2023 | 190 | 0.050 |
Why?
| | Nitroarginine | 3 | 2006 | 47 | 0.050 |
Why?
| | Artifacts | 1 | 2022 | 114 | 0.050 |
Why?
| | Prognosis | 2 | 2019 | 3315 | 0.050 |
Why?
| | Respiration | 1 | 2022 | 180 | 0.050 |
Why?
| | Piperazines | 3 | 2011 | 310 | 0.050 |
Why?
| | Image Enhancement | 1 | 2022 | 158 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2011 | 1836 | 0.040 |
Why?
| | Postoperative Period | 1 | 2021 | 288 | 0.040 |
Why?
| | Soluble Guanylyl Cyclase | 2 | 2011 | 15 | 0.040 |
Why?
| | Pain Management | 1 | 2023 | 285 | 0.040 |
Why?
| | Benzodiazepines | 1 | 2021 | 114 | 0.040 |
Why?
| | Injections, Intra-Arterial | 1 | 2000 | 25 | 0.040 |
Why?
| | Protoporphyrins | 1 | 2000 | 16 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2020 | 9049 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2007 | 1311 | 0.040 |
Why?
| | Perioperative Period | 1 | 2020 | 47 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2021 | 133 | 0.040 |
Why?
| | Colorado | 2 | 2020 | 4090 | 0.040 |
Why?
| | Quinoxalines | 2 | 2011 | 60 | 0.040 |
Why?
| | Injections, Intramuscular | 1 | 2000 | 117 | 0.040 |
Why?
| | Airway Management | 1 | 2020 | 59 | 0.040 |
Why?
| | Proteus | 1 | 2019 | 6 | 0.040 |
Why?
| | Enterobacter | 1 | 2019 | 7 | 0.040 |
Why?
| | Epinephrine | 1 | 2020 | 163 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2007 | 2550 | 0.040 |
Why?
| | Body Temperature Regulation | 1 | 2020 | 72 | 0.040 |
Why?
| | Transportation of Patients | 1 | 2020 | 51 | 0.040 |
Why?
| | Contrast Media | 1 | 2022 | 347 | 0.040 |
Why?
| | Body Temperature | 1 | 2020 | 208 | 0.040 |
Why?
| | Heart Septal Defects, Ventricular | 1 | 2019 | 40 | 0.040 |
Why?
| | Aftercare | 1 | 2021 | 186 | 0.040 |
Why?
| | Operating Rooms | 1 | 2020 | 85 | 0.040 |
Why?
| | Ultrasonography, Prenatal | 1 | 2020 | 237 | 0.040 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2020 | 150 | 0.040 |
Why?
| | Reference Values | 1 | 2000 | 739 | 0.040 |
Why?
| | Benchmarking | 1 | 2020 | 161 | 0.040 |
Why?
| | Cesarean Section | 1 | 2000 | 169 | 0.040 |
Why?
| | Consensus | 1 | 2021 | 532 | 0.040 |
Why?
| | Imaging, Three-Dimensional | 1 | 2022 | 511 | 0.040 |
Why?
| | Surgical Mesh | 1 | 2018 | 40 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2000 | 714 | 0.040 |
Why?
| | Blood Vessels | 1 | 2000 | 179 | 0.040 |
Why?
| | Congenital Abnormalities | 1 | 2018 | 72 | 0.040 |
Why?
| | Program Development | 1 | 2020 | 339 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2002 | 1331 | 0.040 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2002 | 801 | 0.040 |
Why?
| | Sterilization | 1 | 2017 | 11 | 0.040 |
Why?
| | Drug Utilization | 1 | 2018 | 164 | 0.040 |
Why?
| | Risk Assessment | 2 | 2018 | 2958 | 0.040 |
Why?
| | Patient Care Team | 1 | 2021 | 517 | 0.040 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 507 | 0.030 |
Why?
| | Estradiol | 1 | 2000 | 450 | 0.030 |
Why?
| | Acetylcholine | 2 | 2009 | 166 | 0.030 |
Why?
| | Burns | 1 | 2020 | 237 | 0.030 |
Why?
| | Infant Mortality | 1 | 2017 | 91 | 0.030 |
Why?
| | Regression Analysis | 1 | 2018 | 945 | 0.030 |
Why?
| | Staphylococcus aureus | 1 | 2019 | 385 | 0.030 |
Why?
| | Escherichia coli | 1 | 2019 | 723 | 0.030 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 2 | 2005 | 17 | 0.030 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 2 | 2005 | 22 | 0.030 |
Why?
| | Sildenafil Citrate | 2 | 2005 | 57 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 771 | 0.030 |
Why?
| | Purines | 2 | 2005 | 158 | 0.030 |
Why?
| | Comorbidity | 1 | 2018 | 1447 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1206 | 0.030 |
Why?
| | Vaccination | 1 | 2021 | 1202 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2011 | 3861 | 0.030 |
Why?
| | Ketanserin | 1 | 2011 | 12 | 0.020 |
Why?
| | Serotonin 5-HT2 Receptor Antagonists | 1 | 2011 | 10 | 0.020 |
Why?
| | Hysterotomy | 1 | 2011 | 10 | 0.020 |
Why?
| | Kidney | 1 | 2018 | 1182 | 0.020 |
Why?
| | Receptors, Serotonin | 1 | 2011 | 32 | 0.020 |
Why?
| | Sertraline | 1 | 2011 | 26 | 0.020 |
Why?
| | Nitroprusside | 1 | 2011 | 64 | 0.020 |
Why?
| | Fluoxetine | 1 | 2011 | 46 | 0.020 |
Why?
| | Hypertrophy, Right Ventricular | 2 | 2003 | 141 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 6195 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2013 | 493 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 288 | 0.020 |
Why?
| | Indoles | 1 | 2011 | 300 | 0.020 |
Why?
| | Constriction | 1 | 2008 | 45 | 0.020 |
Why?
| | Child, Preschool | 1 | 2022 | 9114 | 0.020 |
Why?
| | Signal Transduction | 3 | 2006 | 4501 | 0.020 |
Why?
| | Regional Blood Flow | 1 | 2008 | 421 | 0.020 |
Why?
| | Risk Factors | 1 | 2019 | 8614 | 0.020 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2004 | 44 | 0.010 |
Why?
| | Organ Size | 1 | 2005 | 434 | 0.010 |
Why?
| | Drug Combinations | 1 | 2005 | 286 | 0.010 |
Why?
| | Heart Atria | 1 | 2004 | 107 | 0.010 |
Why?
| | Neovascularization, Physiologic | 1 | 2005 | 174 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 2004 | 388 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 25 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2003 | 40 | 0.010 |
Why?
| | Aorta | 1 | 2004 | 388 | 0.010 |
Why?
| | Ligands | 1 | 2003 | 556 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2182 | 0.010 |
Why?
| | Physical Stimulation | 1 | 2000 | 76 | 0.010 |
Why?
| | Muscle, Smooth | 1 | 2000 | 142 | 0.010 |
Why?
| | Gene Expression | 1 | 2003 | 1417 | 0.010 |
Why?
| | Rats | 1 | 2005 | 4913 | 0.010 |
Why?
|
|
Grover's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|